Baricitinib as the treatment of choice for hospitalised individuals with COVID-19

Baricitinib as the treatment of choice for hospitalised individuals with COVID-19

Bibliographic Details
Main Authors:	Peter J. Richardson, Justin Stebbing
Format:	Article
Language:	English
Published:	Elsevier 2022-07-01
Series:	EClinicalMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537022002231

Similar Items

The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
by: Peter J. Richardson, et al.
Published: (2022-06-01)

Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials
by: Vijairam Selvaraj, et al.
Published: (2022-07-01)

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
by: Justin Stebbing, et al.
Published: (2020-06-01)

Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19
by: Daniel P. Smith, et al.
Published: (2021-07-01)

Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients’ treatment
by: Alexey I. Khripun, et al.
Published: (2022-06-01)

Baricitinib for the treatment of rheumatoid arthritis
by: Ivan Urits, et al.
Published: (2020-12-01)

Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19
by: Mariacristina Poliseno, et al.
Published: (2023-05-01)

Current Status of Baricitinib as a Repurposed Therapy for COVID-19
by: Maha Saber-Ayad, et al.
Published: (2021-07-01)

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
by: Yuichi Kojima, et al.
Published: (2022-04-01)

A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
by: Dallis Q. Ngo, et al.
Published: (2022-01-01)

Additional baricitinib loading dose improves clinical outcome in COVID-19
by: Hasan Md Jahidul, et al.
Published: (2020-12-01)

Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19
by: Josef Finsterer, et al.
Published: (2021-12-01)

Application of Baricitinib in Dermatology
by: Zhang J, et al.
Published: (2022-03-01)

Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes
by: Brian Dobosh, et al.
Published: (2022-06-01)

Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
by: Jing Sun, et al.
Published: (2023-11-01)

Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis
by: Eduardo Pérez-Alba, et al.
Published: (2021-10-01)

Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
by: Güllü Gencebay, et al.
Published: (2025-03-01)

Successful treatment of cutaneous polyarteritis nodosa with baricitinib
by: Shihui Zhou, et al.
Published: (2024-12-01)

P157 Baricitinib for the treatment of Rhupus Syndrome
by: Jorge Juan Fragío Gil, et al.
Published: (2024-03-01)

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
by: Ekaterina A Bryushkova, et al.
Published: (2022-01-01)

Baricitinib in the Treatment of Patients with COVID-19: A Review of International Data and Analysis of Clinical Results in the Russian Population
by: А. I. Zagrebneva, et al.
Published: (2021-05-01)

Undiagnosed comorbidities among individuals hospitalised with COVID-19 in South African public hospitals
by: W Jassat, et al.
Published: (2022-08-01)

Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects
by: Abdulla Watad, et al.
Published: (2024-07-01)

Alopecia areata treatment with baricitinib: different relapse phenotypes
by: Federica Dall’Oglio, et al.
Published: (2024-12-01)

Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis
by: Roya Mohammadi-Meyabadi, et al.
Published: (2024-09-01)

Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy
by: Yuyang Han, et al.
Published: (2022-10-01)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
by: Weinblatt, M, et al.
Published: (2017)

Autoantibodies in hospitalised patients with COVID‐19
by: Eleni Tiniakou, et al.
Published: (2024-01-01)

A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19
by: Bieber, T, et al.
Published: (2022)

COVID-19: coagulation disorders and anticoagulant treatment in patients hospitalised in ICU
by: Jan Pluta, et al.
Published: (2021-05-01)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
by: Taylor, PC, et al.
Published: (2023)

Efficacy of baricitinib in treatment of coexisting alopecia areata and lichen planopilaris
by: Adaugo A. Sanyi, MD, et al.
Published: (2025-02-01)

Use of Baricitinib in a patient with treatment-resistant pyoderma gangrenosum
by: Kaylin Bechard, et al.
Published: (2024-03-01)

Baricitinib Liposomes as a New Approach for the Treatment of Sjögren’s Syndrome
by: Núria Garrós, et al.
Published: (2022-09-01)

Successful treatment of bullous pemphigoid with baricitinib: A case report
by: Jun Ma, et al.
Published: (2023-01-01)

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
by: Danielle Rogner, et al.
Published: (2022-03-01)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
by: Kawalec P, et al.
Published: (2019-02-01)

Efficacy of baricitinib combined with iguratimod in the treatment of refractory rheumatoid arthritis
by: CHEN Jianming, LEI Meihong, ZHANG Lanxia
Published: (2023-11-01)

Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis
by: Yanxiong Mao, et al.
Published: (2025-01-01)